Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial.

@article{Rasmussen2010EfficacyAS,
  title={Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial.},
  author={Klaus Rasmussen and Michael Maeng and Anne Kjer Kaltoft and Per Thayssen and Henning Kelbaek and Hans Henrik Tilsted and Ulrik Abildgaard and Evald H\oj Christiansen and Thomas Engstr\om and Lars Romer Krusell and Jan L Ravkilde and Peter Riis Hansen and Knud N\orregaard Hansen and Steen Zabell Abildstr\om and Jens Aar\oe and Jan Skov Jensen and Steen Dalby Kristensen and Hans Erik B\otker and Morten G. Madsen and S\oren Paaske Johnsen and Lisette Okkels Jensen and Henrik Toft S\orensen and Leif Thuesen and Jens Flensted Lassen},
  journal={Lancet},
  year={2010},
  volume={375 9720},
  pages={1090-9}
}
BACKGROUND In low-risk patients, the zotarolimus-eluting stent has been shown to reduce rates of restenosis without increasing the risk of stent thrombosis. We compared the efficacy and safety of the zotarolimus-eluting stent versus the sirolimus-eluting stent in patients with coronary artery disease who were receiving routine clinical care with no direct follow-up. METHODS We did a single-blind, all-comer superiority trial in adult patients with chronic stable coronary artery disease or… CONTINUE READING
70 Citations
24 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 70 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 24 references

Kelbaek H, et al, for the SORT OUT II Investigators. Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial

  • AM Galloe, L Thuesen
  • JAMA
  • 2008

Similar Papers

Loading similar papers…